Study: Single daily ribavirin dose doesn't increase adverse effects

03/27/2013 | Medscape (free registration)

Researchers at the Icahn School of Medicine at Mount Sinai in New York found once-daily ribavirin treatment did not increase the risk of adverse gastrointestinal events in hepatitis C patients being treated with triple therapy. The results were presented at the International Conference on Viral Hepatitis.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care